Clin2
NCT06632834Possibly a fitRecruiting

Targeted treatment study for dilated cardiomyopathy

Dilated Cardiomyopathy

Part of Genetic & congenital, Heart & circulation clinical trials.

This study tests whether a personalized treatment approach can improve heart function in people with dilated cardiomyopathy (a condition where the heart becomes enlarged and weak). It focuses on patients who still have low heart function despite standard medications.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
230 people
Ages
birth to 99 years
Study type
Interventional

Who can take part

  • You have been diagnosed with dilated cardiomyopathy (an enlarged, weak heart).
  • Your heart function is low (ejection fraction less than 45%) and your heart is enlarged.
  • You have normal or high cholesterol and triglycerides (fats in your blood).
  • You have been on heart failure medications for at least 1–3 months (depending on your situation) and still have poor heart function.
  • You do not have liver or kidney problems, have not had heart surgery recently, and are not taking certain other medicines.
  • You are not pregnant and are willing to avoid pregnancy during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07241104Recruiting· Phase 1
Study of a new drug for dilated cardiomyopathy with a specific genetic change

This trial tests an experimental drug called AZD4063 for people with dilated cardiomyopathy caused by a specific genetic mutation (R14del in the PLN gene). The goal is to see if the drug can improve heart function and symptoms.

Amsterdam
NCT07210723Recruiting· Phase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy

This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.

Birmingham, Alabama
NCT07293338Recruiting
Heart muscle blood flow study for dilated cardiomyopathy

This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.

Hangzhou, Zhejiang
NCT06741995Recruiting
Testing antibodies to predict heart muscle disease progression

This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.

Wuhan, Hubei
NCT06747429Recruiting
High-fat diet for heart failure metabolism

This trial tests whether a high-fat diet can help change how your heart uses energy, potentially improving heart function in people with non-ischemic heart failure.

Paris
NCT07606274Recruiting· Phase 1/Phase 2
Study of NVC-001 for heart muscle disease caused by LMNA gene change

This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.

Birmingham, Alabama

Hear when a new Dilated Cardiomyopathy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.